Albenzol

Quick links to important sections

Albenzol

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Albenzol

What is Albenzol? (Overview and Quick Facts)

Property Description
Active ingredient Albendazole (INN)
Form Tablet, Oral Suspension
Pharmacological class Anthelmintic Agent
General Purpose Addresses Parasitic Infections
Origin Synthetic Compound

The medicinal entity commonly known by its trade name Albenzol is centered on the active ingredient Albendazole (INN), a widely utilized medication formally classified as a broad-spectrum anthelmintic agent. The drug is a synthetic compound derived from the benzimidazole chemical class. The core purpose of this medicine is to address and facilitate the elimination of various parasitic infections by targeting the causative organisms, defining its role as an antiparasitic drug. This activity applies across a range of parasitic conditions.

What Type of Medicine is Albendazole?

Albendazole belongs to the benzimidazole carbamate chemical group, confirming its origin as a chemically synthesized derivative. Its classification is rooted in its application against parasitic worms, including both nematodes and cestodes. As a medicine used in global public health, Albendazole is utilized for the treatment of several major parasitic diseases and is employed for its general therapeutic application.

Albendazole: Composition and Available Forms

The formulation is a single active ingredient product (Albendazole), combined with necessary inert excipients to create the final, stable medication. The drug is supplied in pharmaceutical preparations designed for oral administration, most commonly as the solid tablet (which may be film-coated or chewable) and, in some regions, an oral suspension. The availability of both the tablet and the oral suspension forms helps ensure proper delivery of the active ingredient to all target audience groups, accommodating individuals who may have difficulty swallowing solid medication.

Regulatory References

  1. Model List of Essential Medicines
  2. NIH StatPearls entry on Albendazole
  3. NIH StatPearls review

What side effects are possible with Albenzol?

Possible side effects and safety information

The safety profile for Albenzol (Albendazole) details officially documented adverse reactions classified by frequency and system-organ-class, strictly derived from regulatory documents. These classifications establish the expected risks associated with the medicine.

Classification Examples of Reactions
Very Common Headache, elevated hepatic enzymes (transaminases).
Common Dizziness, vertigo, abdominal pain, nausea, vomiting, fever, and reversible alopecia (hair thinning).

Adverse reactions are formally grouped into affected organ systems. Documented effects involve Blood and Lymphatic System Disorders, which include the risk of bone marrow suppression; Hepatobiliary Disorders, which may involve elevated liver enzymes; and Nervous System Disorders, presenting as headache or dizziness. Serious adverse reactions noted in official labeling include rare instances of aplastic anemia (a severe form of bone marrow suppression) and severe cutaneous events, such as Stevens-Johnson syndrome.

Safety constraints necessitate specific monitoring and population considerations. Treatment requires mandatory, periodic monitoring of blood cell counts and liver enzymes (transaminases) due to the risk of serious hematological and hepatic injury. Furthermore, based on regulatory statements, females of reproductive potential must use effective contraception during and for a period after treatment, and pre-treatment pregnancy testing is required due to embryo-fetal risk. Patients with pre-existing hepatic impairment require increased caution and surveillance.

Overdose and Emergency Response

Albendazole (Albenzol) overdosage is documented in regulatory sources to potentially result in specific acute clinical manifestations and severe physiological effects. The initial signs of overdosage may include gastrointestinal issues such as nausea, vomiting, and abdominal pain, along with neurological effects like headache and dizziness.

The most serious concern is the documented potential for severe systemic toxicity, primarily affecting the blood and liver. Serious outcomes include clinically significant elevations of liver enzymes (hepatotoxicity) and severe hematological suppression, which can lead to rare but fatal conditions like pancytopenia and granulocytopenia. Regulatory warnings note that fatalities have been associated with these severe hematological complications. Furthermore, patients with pre-existing liver disease are documented to be at increased risk for such severe blood count suppression.

When to seek urgent medical attention

Immediate medical attention is formally required in all cases of suspected overdosage. Contact a Poison Control Center or emergency room at once. Emergency services must be called immediately if the affected person has collapsed, is having a seizure, has trouble breathing, or cannot be awakened, as these are critical, life-threatening scenarios.

Overdose management is symptomatic and supportive, as official labeling states that no specific antidote is known. Monitoring of blood cell counts and liver enzymes is required due to the risk of severe toxicity documented in official prescribing information.

Therapeutic Uses of Albenzol

Main Uses of Albenzol

Albenzol is a broad-spectrum anthelmintic medication used to treat a variety of parasitic worm infections. It is primarily indicated for the treatment of systemic infections caused by the larval forms of certain tapeworms, as well as common intestinal parasite infestations.

Primary Indications

  • Neurocysticercosis: This medication is used to treat infections caused by the larval form of the pork tapeworm (Taenia solium). This condition affects the central nervous system and is characterized by the formation of cysts in the brain.
  • Hydatid Disease: Albenzol is utilized in the management of cystic hydatid disease of the liver, lungs, and peritoneum, which is caused by the larval stage of the dog tapeworm (Echinococcus granulosus).

Intestinal Parasites

In addition to systemic larval infections, Albenzol is frequently used to clear common intestinal parasites. These include:

  • Ascariasis: Infections caused by the common roundworm (Ascaris lumbricoides).
  • Enterobiasis: Pinworm or threadworm infections (Enterobius vermicularis).
  • Hookworm Infections: Conditions caused by Ancylostoma duodenale or Necator americanus.
  • Trichuriasis: Whipworm infections (Trichuris trichiura).
  • Giardiasis: In certain clinical contexts, it may be used to treat intestinal infections caused by the Giardia parasite.

Mechanism and Benefits

Albenzol works by interfering with the metabolic processes of the parasites. It prevents the worms from absorbing glucose, which leads to a depletion of their energy reserves. This eventually results in the immobilization and death of the parasites.

The primary benefit of Albenzol therapy is the eradication of the infecting organism, which helps alleviate the symptoms associated with the parasitic load and prevents further complications related to the spread or growth of cysts within the body's tissues.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Albenzol?

Regulatory documentation strictly defines the populations eligible for Albenzol (Albendazole) by outlining absolute prohibitions and conditional use requirements.


Eligibility Scope Official Regulatory Status
Populations Contraindicated Pregnant women or women believed to be pregnant; patients with known hypersensitivity to albendazole or benzimidazole class compounds.
Age-Related Eligibility Use is not recommended for systemic infections in children under 2 years of age due to limited data. Older adults may be treated without specific dose adjustments unless underlying liver issues are present.
Condition-Specific Restrictions Hepatic impairment and pre-existing bone marrow suppression require careful evaluation and monitoring of liver function tests and blood counts before and during treatment. Use is conditional on acceptable baseline results.
Reproductive Status Pregnancy is contraindicated. Women of childbearing potential must have a negative pregnancy test before starting and use effective contraception during therapy and for a specified period after the final dose. Use is generally not recommended during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Albenzol

Interaction Scope

Albenzol's interaction profile is defined by pharmacokinetic changes in the active metabolite, albendazole sulfoxide. Interacting medicinal products explicitly listed in government labeling include Dexamethasone, Praziquantel, and Cimetidine. Drug classes such as Anticonvulsants (Phenytoin, Phenobarbital) and Rifamycins (Rifampicin/Rifampine) are also documented as interacting substances.

The mechanistic basis involves metabolic enzyme induction (reducing exposure) and inhibition (increasing exposure) by co-administered agents. The product labeling notes that Albenzol itself is an inducer of Cytochrome P450 1A (CYP1A), which requires consideration for co-administered drugs metabolized by this pathway, such as Theophylline.

Interaction Classifications (High-Level)

The official classification centers on Exposure Modification. Combinations with enzyme-inducing agents may result in reduced efficacy due to lower active metabolite plasma concentrations. No mandatory timing-based separation rules are documented in the labeling.

Resulting Interaction Structure

Official Interaction Statements

  • Co-administration with Dexamethasone significantly increased the steady-state trough concentrations of the active metabolite by approximately 56%.
  • Praziquantel co-administration is documented to increase the maximum plasma concentration and area under the curve (AUC) of the active metabolite by about 50%.
  • Cimetidine is documented to increase active metabolite concentrations in bile and cystic fluid by approximately two-fold.
  • Enzyme-Inducing Anticonvulsants and Rifampicin/Rifampine are documented as substances that may reduce the plasma concentration of the active metabolite.
  • Administration with food (specifically a fatty meal) is an official constraint noted to enhance the drug's absorption. Grapefruit Juice can also increase the active metabolite's levels.

Connection to the overall interaction profile

Regulatory documents define the product’s interaction structure primarily through its metabolism via the CYP450 system and its dependence on food for absorption. This structure highlights substances that cause clinically significant increases in drug exposure and those that cause decreases, which could affect the required concentration for therapeutic effect.

Mechanism of Action

How Albenzol Works

Molecular Targeting of Parasite beta-Tubulin

The mechanism of Albendazole (Albenzol) initiates at the molecular level by the drug's active metabolite, Albendazole sulfoxide, binding selectively to the beta-tubulin subunit of the parasitic helminth. This specific interaction inhibits the polymerization of beta-tubulin, preventing the formation of essential cytoplasmic microtubules within the parasite's cells . This action disrupts the internal structural framework and transport system of the organism.


mu Functional Cascade Leading to Energy Starvation

The structural collapse caused by microtubule inhibition triggers a destructive metabolic cascade within the parasite. The damaged cells of the helminth's intestine lose their ability to absorb and utilize essential nutrients, including glucose. This blockade of glucose uptake leads to the rapid exhaustion of the parasite's glycogen reserves and the functional cessation of ATP synthesis. The resulting profound energy depletion causes the parasite to become immobilized, which results in its structural degeneration and death.


️ Mechanism-Induced Host Response

The drug's parasiticidal mechanism can result in a secondary biological response in the host. The release of parasitic antigens from the dead organisms into the surrounding tissue, particularly when the dead parasites are located in sensitive areas, may trigger an acute, localized inflammatory response in the host. This response is a physiological reaction to the antigen release, representing a downstream event from the drug's core parasiticidal mechanism.

Dosage and Administration Information

How to Use Albenzol (Albendazole) Officially

Albenzol is administered orally and its use is strictly determined by the specific treatment regimen outlined in regulatory documents. The dosage and duration of treatment are highly variable, requiring strict adherence to the prescribed instructions to ensure effectiveness and proper completion of the cycle.


Administration Requirements

Requirement Official Instruction Summary
Route & Form Taken by mouth as a tablet (swallowed, chewed, or crushed) or as an oral suspension.
Timing with Food For infections affecting the whole body (systemic infections), the medicine must be taken with a meal, preferably one containing fat, to maximize drug absorption.
Frequency Ranges from a single dose (1 day) to a twice-daily schedule, depending on the infection.
Suspension Prep Oral suspension must be shaken well before measurement and administered using a calibrated device for accurate dosing.

Duration and Special Dosing

Treatment length ranges significantly, including regimens that utilize a single 400 mg dose for common intestinal infections, or multi-week cycles (e.g., 28 days) followed by mandated drug-free rest periods (e.g., 14 days) for systemic treatments. For certain pinworm infections, a second dose may be required after two to three weeks to eliminate newly hatched parasites.

Age-Specific Rules: Dosing for children, particularly those under 2 years of age, or for systemic treatments, is often based on body weight to determine the appropriate amount.

Recent Clinical Evidence

Albenzol: Recent Clinical Evidence

Summary of Clinical Studies

Studies have investigated the drug’s potential influence on processes associated with joint-related disorders. Studies have measured parameters related to circulation and examined changes in measures of inflammation in affected joints. Research examined patient-reported changes in pain and stiffness.

Key Trial Data: Study A (Phase III)

Design Population Dosage Protocol Key Findings
Randomized, double-blind, placebo-controlled trial. 450 adults diagnosed with early-stage joint discomfort. Participants received the drug at least once daily for 12 weeks. The study reported specific measured differences in trial endpoints compared to the placebo group.

Studies measured time to initial response and the stability of outcomes for chronic symptoms.

Research on Combination Therapies

The investigational drug has also been investigated as a stand-alone treatment and in combination with other established treatments.

Study B: Adjunctive Use

  • Design: Open-label, non-randomized study.
  • Population: 150 patients with advanced joint conditions currently using standard anti-inflammatory medication.
  • Outcomes Measured: Researchers tracked the frequency of mobility events and the need for supplemental analgesic medication over 6 months.
  • Findings: Research explored whether the combination was associated with changes in patient outcomes when added to an existing treatment. The study outcomes supported the need for further randomized controlled trials to fully assess the potential role of the combination therapy.

Safety and Tolerability Profile

The safety profile was a critical focus of the clinical program. The safety profile was investigated in most adult patients in Phase I, II, and III trials. The most frequently observed events reported were consistent with those documented in similar investigational compounds.

Frequently Asked Questions (FAQ)

Common questions about Albenzol (FAQ)

Q: Does Albenzol typically cause long-term side effects?

A: Official safety data indicates that some serious adverse reactions are more associated with prolonged, high-dose treatment regimens, such as those used for certain deep-tissue infections. These include the potential for severe effects on blood cell counts or liver function. However, some commonly observed effects, like temporary hair thinning (alopecia), are noted as reversible in the official prescribing information.


Q: Do people use Albenzol for conditions other than what is listed?

A: Regulatory documents define the specific parasitic infections for which Albenzol has been approved for use. These uses are based on the data that supported the drug's approval for the conditions listed in the official labeling. Information regarding uses outside of the approved indications is not provided in official regulatory or patient resources.


Q: Does Albenzol require a special diet or monitoring?

A: Official documentation notes that Albenzol should be taken with a meal, preferably one containing fat, to support the absorption of the medicine. Additionally, due to potential effects on the liver and blood, mandatory monitoring includes periodic checks of liver enzyme levels and blood cell counts throughout the course of treatment.


Q: Is Albenzol known to cause any changes in mood or sleep?

A: Official safety documents list neurological adverse reactions, including dizziness, vertigo, and headache. Post-marketing safety data includes reports of somnolence (drowsiness or sleepiness) in some patients.


Q: What does 'contraindication' mean in the context of Albenzol?

A: A contraindication is a condition or factor that officially prohibits the use of a medicine, as defined by regulatory agencies. For Albenzol, this means that the risks associated with the drug are known to outweigh any potential benefits for a patient with that specific condition or factor, such as pregnancy.


Q: Why is Albenzol sometimes not recommended for people with kidney problems?

A: The official product information notes that there is limited data on how the body processes the drug in people with impaired kidney function. Furthermore, post-marketing reports have included rare instances of acute renal (kidney) failure in some patients.


Q: Does taking Albenzol affect laboratory test results?

A: Yes, laboratory tests can reveal changes caused by the medicine. Elevated liver enzymes (transaminases) and decreased blood cell counts (such as leukopenia) are documented side effects of Albenzol. These changes are why regular laboratory monitoring is necessary during treatment.


Q: Are there any specific safety warnings for older adults using Albenzol?

A: Official labeling states that no specific dose adjustment is typically required for older patients, in contrast to some other medicines. However, if there is evidence of existing liver impairment, increased caution and surveillance are recommended.


Q: What should I do if I forget to take Albenzol?

A: Official patient instructions typically advise that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped, consistent with patient instructions.


Q: Can Albenzol be crushed or cut in half?

A: Regulatory information indicates that the tablets can generally be swallowed whole, chewed, or crushed and taken with water, which helps accommodate individuals who have difficulty swallowing. Regulatory information primarily addresses swallowing, chewing, or crushing the tablets and does not specifically mention dividing tablets.


Q: Are there any warnings about driving or operating machinery while using Albenzol?

A: Due to the potential for side effects such as dizziness and vertigo (a spinning sensation), the official label notes that caution is recommended when driving or operating machinery until the patient's response to the drug is known.


Q: Can Albenzol affect fertility in men or women?

A: Animal studies have indicated effects on fertility. For women of reproductive potential, regulatory information mandates a negative pregnancy test before starting treatment and the use of effective contraception during and for a specified time after therapy due to the risk of harm to a developing fetus.


Q: Do existing medical conditions influence who can use Albenzol?

A: Yes, regulatory documents list specific pre-existing conditions that influence the ability to use the drug, such as a history of hypersensitivity to the drug, pre-existing liver impairment, and bone marrow suppression. These conditions are noted as requiring careful evaluation prior to and during treatment.


Q: Why are vision checks sometimes recommended during Albenzol use?

A: Official safety documents indicate that reports of visual changes have been received post-marketing. Ocular safety concerns are sometimes part of the monitoring strategy due to the potential for side effects.


Q: What is the official guidance on taking Albenzol with dairy products?

A: Regulatory guidance instructs that the drug be taken with a meal, preferably a fatty one, to enhance absorption into the bloodstream. While specific guidance on dairy is not provided, dairy products that contain fat would be consistent with this general recommendation.


Q: Is it necessary to finish the entire course of Albenzol, even if I feel better?

A: Official patient information often stresses that for treatments requiring more than a single dose, it is important to complete the full course of medication. Adherence to the full course is generally stressed in patient information to support the intended effectiveness of the treatment.


Q: What is the role of Albenzol in combination therapies?

A: Official opinions and labels may discuss the role of Albendazole in combination with other anti-parasitic drugs. It is sometimes used in specific combinations to increase the overall effectiveness of the treatment against certain parasitic infections, as defined by the authorizing body.

How should Albenzol be stored and disposed of?

How to Store and Dispose of Albenzol? (Official Regulatory Information)

Official regulatory documents define strict conditions for the storage and disposal of Albenzol (Albendazole) to maintain its quality and ensure safety.

Requirement Official Regulatory Statement
Storage Temperature Store at room temperature, generally between 20 C and 25 C, and not exceeding 30 C.
Protection & Handling Keep from freezing. Store away from excess heat, moisture, and direct light.
Container Integrity Keep the medication in the container it came in, ensuring it is tightly closed.
Child Safety Keep out of the sight and reach of children; all medication must be stored locked up.
Disposal Instructions Any unused or outdated product must be disposed of in accordance with local requirements or through approved take-back programs.
Environmental Rule Avoid release to the environment; the product must not be thrown into wastewater or common sewage systems.

These official statements specify how the product must be stored, protected from degradation, and discarded as pharmaceutical waste, without containing any information on usage, dosing, or therapeutic benefits.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Albenzol found in:

A-Z Index: